Innoviva EPS - Earnings per Share 2012-2026 | INVA
Innoviva eps - earnings per share from 2012 to 2026. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Innoviva Annual EPS | |
|---|---|
| 2025 | $3.30 |
| 2024 | $0.36 |
| 2023 | $2.20 |
| 2022 | $2.37 |
| 2021 | $2.87 |
| 2020 | $2.02 |
| 2019 | $1.43 |
| 2018 | $3.53 |
| 2017 | $1.17 |
| 2016 | $0.53 |
| 2015 | $-0.16 |
| 2014 | $-1.50 |
| 2013 | $-1.67 |
| 2012 | $-0.20 |
| 2011 | $-1.41 |
| Innoviva Quarterly EPS | |
|---|---|
| 2026-06-30 | $-1.14 |
| 2026-03-31 | $2.22 |
| 2025-12-31 | $2.19 |
| 2025-09-30 | $1.08 |
| 2025-06-30 | $0.77 |
| 2025-03-31 | $-0.74 |
| 2024-12-31 | $0.43 |
| 2024-09-30 | $0.02 |
| 2024-06-30 | $-0.55 |
| 2024-03-31 | $0.46 |
| 2023-12-31 | $0.78 |
| 2023-09-30 | $0.98 |
| 2023-06-30 | $0.02 |
| 2023-03-31 | $0.42 |
| 2022-12-31 | $-0.64 |
| 2022-09-30 | $2.80 |
| 2022-06-30 | $0.01 |
| 2022-03-31 | $0.20 |
| 2021-12-31 | $0.23 |
| 2021-09-30 | $0.90 |
| 2021-06-30 | $0.90 |
| 2021-03-31 | $0.84 |
| 2020-12-31 | $0.48 |
| 2020-09-30 | $0.26 |
| 2020-06-30 | $0.69 |
| 2020-03-31 | $0.59 |
| 2019-12-31 | $0.42 |
| 2019-09-30 | $0.36 |
| 2019-06-30 | $0.34 |
| 2019-03-31 | $0.31 |
| 2018-12-31 | $2.34 |
| 2018-09-30 | $0.43 |
| 2018-06-30 | $0.49 |
| 2018-03-31 | $0.27 |
| 2017-12-31 | $0.51 |
| 2017-09-30 | $0.21 |
| 2017-06-30 | $0.30 |
| 2017-03-31 | $0.15 |
| 2016-12-31 | $0.23 |
| 2016-09-30 | $0.13 |
| 2016-06-30 | $0.13 |
| 2016-03-31 | $0.04 |
| 2015-12-31 | $0.04 |
| 2015-09-30 | $-0.04 |
| 2015-06-30 | $-0.07 |
| 2015-03-31 | $-0.09 |
| 2014-12-31 | $-0.12 |
| 2014-09-30 | $-0.19 |
| 2014-06-30 | $-0.57 |
| 2014-03-31 | $-0.62 |
| 2013-12-31 | $-0.47 |
| 2013-09-30 | $-0.44 |
| 2013-06-30 | $-0.37 |
| 2013-03-31 | $-0.39 |
| 2012-12-31 | $-0.33 |
| 2012-09-30 | $-0.37 |
| 2012-06-30 | $-0.42 |
| 2012-03-31 | $0.93 |
| 2011-12-31 | $-0.45 |
| 2011-09-30 | $-0.37 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.506B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1069.485B | 36.08 |
| Johnson & Johnson (JNJ) | United States | $643.925B | 24.60 |
| AbbVie (ABBV) | United States | $464.737B | 24.20 |
| Merck (MRK) | United States | $354.755B | 44.79 |
| Roche Holding AG (RHHBY) | Switzerland | $350.029B | 0.00 |
| Novartis AG (NVS) | Switzerland | $264.508B | 15.97 |
| Novo Nordisk (NVO) | Denmark | $189.896B | 10.58 |
| Pfizer (PFE) | United States | $157.026B | 9.03 |
| Sanofi (SNY) | France | $102.796B | 8.65 |
| Bayer (BAYRY) | Germany | $55.158B | 9.81 |